Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma
Sponsor: University Hospital, Bordeaux
Summary
Allogeneic stem cell transplantation (Allo-SCT) in multiple myeloma (MM) remains a controversial topic because of a high risk of relapse and a significant transplant-related mortality (TRM). In an effort to reduce the TRM, most allogeneic transplants in MM are now performed after reduced-intensity conditioning regimens. In these conditions, TRM usually range from 10 to 20%. However, reducing the intensity of the conditioning invariably increases the incidence of relapse to 45 to 60%. As a consequence, post-transplant strategies to reduce the incidence of relapse after reduced-intensity Allo-SCT should be considered and evaluated.
Official title: Safety of a Maintenance Therapy With Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Chemosensitive Relapsed Multiple Myeloma
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
13
Start Date
2011-08
Completion Date
2014-10
Last Updated
2026-05-22
Healthy Volunteers
No
Conditions
Interventions
Lenalidomide
Start between Day+100 and Day+120 post-transplant \- Initial dose: 5 mg/day every day In the absence of thrombocytopenia \< 75000/mm3 or neutropenia \< 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day. \- Duration * until persistent stringent complete response for 3 months * or progression defined by IMWG criteria12 * or unacceptable toxicity * or one year after transplant
Locations (1)
CHU Bordeaux - Hôpital Haut-Lévêque
Pessac, France